CompletedNCT06254612
SP-624 safety and efficacy study for adult depression
About this title
Read the official source — NCT06254612Researchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Phoenix and 49 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: March 25, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 497
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06254612
- Official title
Show the full official title
A Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix · Tucson · Bryant
46 more locations
- Bellflower
- Imperial
- Lemon Grove
- Oceanside
- Riverside
- Torrance
- Walnut Creek
- West Covina
- Colorado Springs
- Jacksonville
- Lakeland
- Lauderhill
- Miami Lakes
- Orlando
- Pinellas Park
- Atlanta
- Meridian
- Elgin
- Marrero
- Boston
- Bloomfield Hills
- Saint Charles
- Lincoln
- Las Vegas
- Cherry Hill
- Marlton
- Albuquerque
- Brooklyn
- New York
- Cary
- Chapel Hill
- Charlotte
- Beachwood
- Dayton
- Middleburg Heights
- Portland
- North Charleston
- Memphis
- Austin
- Dallas
- El Paso
- Richardson
- Stafford
- Wichita Falls
- Bellevue
- Everett
Questions about this study
What did researchers investigate?
Researchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Sirtsei Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including SP-624 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
